Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc. has strengthened its outlook for bitopertin, raising the probability of FDA approval to 100% from 75%, which may significantly enhance its market entry potential and revenue streams. The company's projections for near to medium-term sales demonstrate robust growth potential, with estimated revenues of $35 million in 2026, escalating to $615 million by 2029, driven by favorable adjustments in launch expectations. Additionally, the acquisition of a Commissioner’s National Priority Voucher (CNPV) for bitopertin is likely to expedite the drug application review process, further bolstering the company's value proposition in the competitive biopharmaceutical landscape.

Bears say

Disc Medicine Inc faces significant challenges that contribute to a negative outlook on its stock. The company is exposed to intellectual property risks that could lead to increased competition and the need for additional financing, posing threats to its revenue generation and overall valuation. Furthermore, there are concerns regarding the clinical efficacy and safety of its product candidates, particularly in the context of regulatory approvals, which could hamper the successful commercialization of its drug pipeline.

IRON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 10 analysts, IRON has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.